Unapproved Drugs in the United States and the Food and Drug Administration

Total Page:16

File Type:pdf, Size:1020Kb

Unapproved Drugs in the United States and the Food and Drug Administration Adv Ther (2011) 28(10):842-856. DOI 10.1007/s12325-011-0059-4 REVIEW Unapproved Drugs in the United States and the Food and Drug Administration Alexander Nasr ∙ Thomas J. Lauterio ∙ Matthew W. Davis Received: May 17, 2011 / Published online: September 1, 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com ABSTRACT unapproved and illegally marketed drugs into the approval process, or discontinuing their Despite more than a century of evolving federal manufacture, distribution, and sale. The FDA has legislation, there remain many unapproved been actively pursuing control of unapproved drugs on the United States (US) market. This drugs in recent years, with an approach article reviews the history of drug approval in the concentrating on drug safety to ensure optimal US, beginning with the landmark Pure Food and public health and consumer protection. Drug Act of 1906, through to the development of the US Food and Drug Administration (FDA). Keywords: drug approval; FDA; unapproved The Pure Food and Drug Act of 1906 was the drugs first comprehensive federal legislation covering drug regulation. Intervening legislation, such INTRODUCTION as the Federal Food, Drug, and Cosmetic Act of 1938 and Kefauver-Harris Amendments in 1962, The United States (US) Food and Drug was later instituted. In June 2006, a century after Administration (FDA) has grown over the the development of the FDA as an enforcement past century, from a single, unidentified body, an initiative was undertaken to remove chemist in 1862 in the US Department of unapproved drugs from the marketplace. The Agriculture to the present-day organization Marketed Unapproved Drugs - Compliance dedicated to promoting and protecting Policy Guide outlines enforcement policies public health through the regulation of drugs aimed at efficiently and rationally bringing all and other products within its purview (Figure 1). The Pure Food and Drug Act of 1906 was the first comprehensive federal legislation covering drug regulation. This Alexander Nasr ∙ Thomas J. Lauterio (*) ∙ article reviews the history of drug approval Matthew W. Davis in the US, from the landmark 1906 Act URL Pharma, Inc., Mutual Pharmaceutical Company, through significant intervening legislation Inc., 1100 Orthodox Street, Philadelphia, PA 19124. Email: [email protected] and development of the FDA, culminating Adv Ther (2011) 28(10):842-856. 843 a century later when, in June 2006, the Marketed Unapproved Drugs - Compliance FDA announced an initiative to remove Policy Guide,1 outlines enforcement policies unapproved drugs from the marketplace, designed to efficiently shepherd all such many of which remain illegally marketed. drugs through the approval process. In recent Final guidance for this initiative, the years, the FDA has stepped up its oversight Figure 1. Timeline of the development of the FDA and subsequent regulatory actions.1 ANDA=Abreviated New Drug Application; CDER=Center for Drug Evaluation and Research; DESI=Drug Efficacy Study Implementation; FDA=Food and Drug Administration; GRAS/E=Generally Recognized as Safe and Effective; NDA=New Drug Application; OTC=Over-the-counter. Federal Pure Food & Drug Act: Durham-Humphrey Amendment: OTC drug review: adulteration/misbranding prescription versus OTC monograph process 1906* 1951‡ 1972|| Sullivan decision Prescription Drug Wrap-up 1948 1984¶ 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 Federal Food, Drug, and Cosmetic Upjohn versus Fitch Act: safety preapproval (GRAS/E) 1970 1938† Kefauver-Harris amendments: The Marketed Unaprroved Drugs efficacy preapproval (DESI) Compliance Policy Guide (CDER) 1962§ 2006# *Also known as the Wiley act; changed the government’s handling of the adulteration and misbranding of food and drugs, and supported national food and drug regulation through public advocacy. †Provisions included the ability of the FDA to require evidence of safety for new drugs, determine standards for food, and inspect factories. ‡Created the line between prescription and nonprescription drugs in that dangerous drugs could not be dispensed without a prescription and mandated that prescription drugs bear the following legend: “Caution: Federal law prohibits dispensing without prescription.” §Established the FDA’s control over clinical drug trials and mandated “good manufacturing practices.” ||OTC drugs marketed in accordance with a final monograph do not require approval of a marketing application by FDA. ¶Also known as DESI-2. Drugs are considered to be marketed illegally unless “grandfathered” or not otherwise a new drug. #FDA’s CDER; superseded previous policies of marketing new drugs without approved NDAs or ANDAs. 844 Adv Ther (2011) 28(10):842-856. and continues to actively pursue control of influence of preservatives on human nutrition unapproved drugs, examples of which are in 1902, which extended to the analyses of also presented in this review. proprietary medicines and plant drugs in the following year.3 These actions occurred at a Methods time when the US marketplace was awash with adulterated food, drug, and biologic products. A thorough search of the published literature, Drug makers were able to produce and sell including that available on MEDLINE/PubMed, products that, in today’s marketplace, would be was used to identify the materials referenced in considered adulterated. For example, “Peter’s this manuscript. Specific search terms, including, Specific, The Great Blood Purifier System but not limited to, FDA, history, development, Regulator” was recommended as a treatment compliance, nitroglycerin, thalidomide, for dermatologic diseases and as an alternative colchicine, and DESI, were used to perform the tonic, invigorator, and blood purifier.3 comprehensive search. In addition, archived The label stated little, if any, of the ingredients, files from the FDA were also accessed. yet it was available and sold legally in the US. Another example was morphine-laced HISTORY OF DRUG APPROVAL IN “Mrs. Winslow’s Soothing Syrup” used for THE US teething and colicky babies.3 While Wiley realized the need for The Pure Food and Drug Act of 1906 enforcement and change of this unregulated marketplace, it is widely believed that the 1906 Few federal laws to regulate the sale and “muckraking” novel The Jungle, by the Pulitzer contents of food and pharmaceuticals in the US Prize-winning American author Upton Sinclair, existed prior to the creation of the Pure Food was the final driving force, resulting in a meat and Drug Act, which was signed into law in inspection law and a comprehensive food and 1906 by President Theodore Roosevelt. This drug law.4 Sinclair’s novel exposed conditions act is also known as the Wiley Act, in honor of in the US meat-packing industry and caused a its main advocate, Harvey Wiley, who is often public uproar, which contributed, in part, to the referred to as the “Father of the FDA.” Wiley implementation of the Meat Inspection Act, as was offered the position of Chief Chemist in the well as the Pure Food and Drug Act a few months US Department of Agriculture in 1882. On after publication of the book.5 assuming this role in 1883, he immediately More than 200 laws would eventually follow changed the government’s handling of the the Pure Food and Drug Act of 1906, leading to adulteration and misbranding of food and one of the most comprehensive and effective drugs, and supported national food and drug public health and consumer protection networks regulation by spurring public indignation over in the world. The Bureau of Chemistry enforced the issue. Motivated by his work with Alice the Act until 1927, when it was reorganized Lakey, one million American women wrote to to establish the Food, Drug, and Insecticides the White House in support of the Pure Food Administration, which was renamed the FDA in and Drug Act.2 1931.5 The regulatory emphasis of the bureau Historically, under Wiley’s guidance, the during Wiley’s tenure was foods, because he Bureau of Chemistry began analyzing the believed they presented more of a threat to Adv Ther (2011) 28(10):842-856. 845 public health than adulterated or misbranded permitted to “manipulate statutory protections drugs. After Wiley’s resignation in 1912, more to inappropriately delay competition.” Those attention was focused on drug regulation, who attempt to do so are then reported to the including the so-called “patent medicines.”5 Federal Trade Commission (FTC). An NDA was not required under a “grandfather clause” for The Federal Food, Drug, and Cosmetic Act drugs marketed prior to 1938 that had been of 1938 previously labeled as “Generally Recognized as Safe and Effective (GRAS/E).” They were The next milestone in the evolution of the required, however, to contain the same chemical FDA was the Food, Drug, and Cosmetic (FD&C) composition, indications, and conditions for use Act of 1938, which was passed after a series of as the “grandfathered drug.”5 disreputable incidents involving drug marketing The FD&C Act of 1938 also mandated the claims which resulted in highly publicized listing of active ingredients on the drug label, deaths. One major incident involved the legally and required labeling with adequate directions marketed Elixir Sulfanilamide, which killed for use and warnings. By 1940, the FDA had at least 105 people, including many children, developed more than two-dozen standardized in the spring of 1937.6 Elixir Sulfanilamide, warning statements for different drugs and the first antimicrobial sulfa drug used to treat determined
Recommended publications
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Daniel Bovet
    D ANIEL B OVET The relationships between isosterism and competitive phenomena in the field of drug therapy of the autonomic nervous system and that of the neuromuscular transmission Nobel Lecture, December 11, 1957 Putting to good use the vast possibilities which organic synthesis offers, a number of workers have directed their efforts towards applying it to thera- peutics, and have sought to establish the bases of a science of pharmaceutical chemistry, or, more exactly perhaps, the bases of a science of chemical pharmacology worthy of this name. If such an ambitious programme has not yet been fully realized, we are at least justified in recognizing, in the work which has now been in progress for fifty years, the appearance of a few guiding principles whose value has not ceased to assert itself. This is particularly true, for example, in the case of ideas in isosterism and com- petition. The origin of many drugs must be looked for in substances of a biological nature, and in particular in the alkaloids. The elucidation of their structure has been a starting-off point for chemists to synthesize similar compounds. Cocaine, atropine, and morphia are particularly good examples in this respect, since substances which are made like them have shown, clinically, local anaesthetic, antispasmodic, and marked analgesic properties, respective- ly. In each of these cases the physiological properties of the new compound seem to be similar to the compound to which it is structurally related. This has been verified in many other fields, but it is nevertheless evident that in certain cases, molecules which are chemically closely related have very dif- ferent and even antagonistic properties.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0281875A1 Srinivasan Et Al
    US 2005O281.875A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0281875A1 Srinivasan et al. (43) Pub. Date: Dec. 22, 2005 (54) PROMETHAZINE CONTAINING DOSAGE Related U.S. Application Data FORM (63) Continuation-in-part of application No. 10/736,902, (75) Inventors: Viswanathan Srinivasan, The filed on Dec. 17, 2003. Woodlands, TX (US); Ralph Brown, Southlake, TX (US); David Brown, Publication Classification Colleyville, TX (US); Himanshu Patel, North Richland Hills, TX (US) (51) Int. Cl." ........................ A61K 3.1/5415; A61K 9/24 (52) U.S. Cl. ......................................... 424/472; 514/225.8 Correspondence Address: GREENBLUM & BERNSTEIN, P.L.C. ABSTRACT 1950 ROLAND CLARKE PLACE (57) RESTON, VA 20191 (US) A pharmaceutical dosage form which comprises promethaz (73) Assignee: Sovereign Pharmaceuticals, Ltd., Fort ine and/or a pharmaceutically acceptable Salt thereof. The Worth, TX dosage form is capable of providing a promethazine plasma concentration within a therapeutic range for at least about 24 (21) Appl. No.: 11/102,725 hours per Single dose. This Abstract is neither intended to define the invention disclosed in this specification nor (22) Filed: Apr. 11, 2005 intended to limit the Scope of the invention in any way. US 2005/0281875 A1 Dec. 22, 2005 PROMETHAZINE CONTAINING DOSAGE FORM or in combination with another drug, for example, pseu doephedrine, is indicated, could obtain relief by ingesting CROSS-REFERENCE TO RELATED only one dosage per 24 hour period. Not only would this APPLICATIONS convenient dosage form increase compliance with ambula tory patients, it would also simplify dosage for patients in 0001. The present application is a continuation-in-part of institutional care, Such as nursing homes and hospitals, U.S.
    [Show full text]
  • POISONS LIST APPENDIX Amoebicides: Carbarsone
    POISONS LIST APPENDIX Amoebicides: Carbarsone Clioquinol and other halogenated hydroxyquinoline compounds Dehydroemetine; its salts Diloxanide; its compounds Dimetridazole Emetine Ipronidazole Metronidazole Pentamidine; its salts Ronidazole Anaesthetics: Alphadolone acetate Alphaxolone Desflurane Disoprofol Enflurane Ethyl ether Etomidate; its salts Halothane Isoflurane Ketamine; its salts Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine Diperodon Etidocaine Levobupivacaine Lignocaine Mepivacaine Orthocaine Oxethazaine Phenacaine Phenodianisyl Prilocaine Ropivacaine Phencyclidine; its salts Propanidid Sevoflurane Tiletamine; its salts Tribromoethanol Analeptics and Central Stimulants: Amiphenazole; its salts Amphetamine (DD) Bemegride Cathine Cathinone (DD) Dimethoxybromoamphetamine (DOB) (DD) 2, 5-Dimethoxyamphetamine (DMA) (DD) 2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD) Ethamivan N-Ethylamphetamine; its salts N-Ethyl MDA (DD) N-Hydroxy MDA (DD) Etryptamine (DD) Fencamfamine Fenetylline Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane Leptazol Lobelia, alkaloids of Meclofenoxate; its salts Methamphetamine (DD) Methcathinone (DD) 5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD) Methylenedioxyamphetamine (MDA) (DD) 3, 4-Methylenedioxymetamphetamine (MDMA) (DD) Methylphenidate;
    [Show full text]
  • Codeine and Its Alternates for Pain and Cough Relief
    Codeine and its Alternates for Pain and Cough Relief 3. The Antitussive Action of Codeine-Mechanism, Methodology and Evaluation This report-the third of a series on codeine and its alternates for pain and cough relief-presents a detailed review of the physiology and pathophysiology of cough, the methods for the experimental and clinical measurement of the antitussive action of drugs, possible mechanisms of action of antitussive agents, and includes a compilation of experi­ mental results and clinical experience with codeine as an antitussive. CONTENTS INTRODUCTION 127 PHARMACOLOGICAL COMPONENTS OF THE ANTITUSSIVE EFFECT • MECHANISM AND SIGNIFICANCE OF COUGH 128 136 ANTITUSSIVE ACTION OF CODEINE 143 METHODS FOR THE STUDY OF ANTITUSSIVE RESUME 153 ACTION 130 REFERENCES 154 INTRODUCTION of codeine has increased greatly in recent years (see Part 4) but the popularity of codeine continues and Codeine was first used as a therapeutic antitussive its annual consumption remains at a high level, paral­ agent soon after its separation as an alkaloidal entity leling the high frequency of need for relief of cough (Martin, 1834) and some of the earliest accounts of as a symptom, especially chronic cough. Bickerman dosage and of the circumstances of its use are sum­ (1960) estimated, not so long ago, that 13% of the marized by K.rueger, Eddy & Sumwalt (1943). population of the United States of America was more Codeine has indeed dominated the picture with than 65 years old and that there were not less than respect to the symptomatic management of cough, 1 300 000 chronic coughers. Watt (1958) estimated with only minor variations, and this situation has that in the United Kingdom of Great Britain and been influenced little by the intro,duction of sub­ Northern Ireland 10% of all prescriptions were for stances claimed to be superior in effectiveness and cough relief.
    [Show full text]
  • Pharmacological Therapies Against Soman-Induced Seizures in Rats 30 Min
    (Review) Choice of approaches in developing novel medical countermeasures for nerve agent poisoning Trond Myhrer, Pål Aas Norwegian Defence Research Establishment (FFI), Protection and Societal Security Division, P. O. Box 25, NO-2027 Kjeller, Norway Running title: Nerve agent poisoning and countermeasures Correspondence: Pål Aas Norwegian Defence Research Establishment (FFI) Protection and Societal Security Division P O Box 25 NO-2027 Kjeller, Norway Phone: +47 63 80 78 43 Fax: +47 63 80 75 09 E-mail: [email protected] Dette er en postprint-versjon / This is a postprint version. DOI til publisert versjon / DOI to published version: 10.1016/j.neuro.2014.04.011 2 Abstract During the establishment of a research branch, all relevant matters encountered will be of interest to study. After having acquired a body of basal knowledge, it becomes possible to derive ideas or hypotheses for further elaboration of information. The purpose of the present study was to show that therapies for nerve agent poisoning based on specific neuropharmacological approaches can have greater probability for being successful than treatment regimens based on fragmental research or serendipitous discoveries. By following the guidelines for research in experimental epilepsy, neuronal target areas for nerve agents have been identified through lesion studies, and critical receptors for pharmacological treatment have been specified through microinfusion studies of rats. Subsequent experimentations have shown that the results achieved from microinfusion studies are transferable to systemic administration. It is demonstrated that a treatment regimen developed through the novel approach is more efficacious than regimens derived from conventional research on countermeasures. A therapy consisting of HI-6, levetiracetam, and procyclidine that has been worked out along the new lines, exerts powerful anticonvulsant capacity and appears to have universal utility as a stand-alone therapy against soman intoxication in rats.
    [Show full text]
  • Cutaneous Analgesia and Systemic Toxicity of Carbetapentane And
    Manuscript 1 Cutaneous analgesia and systemic toxicity of carbetapentane and caramiphen in rats Ching-Hsia Hunga , Ph.D., Chin-Chen Chub, M.D., Ph.D., Yu-Chung Chenc, M.S., Kuo-Sheng Liud, Ph.D., Yu-Wen Chenb,e,*, Ph.D., Jhi-Joung Wangb, M.D., Ph.D. a Institute & Department of Physical Therapy, National Cheng Kung University, Tainan, Taiwan; b Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan; c Division of Physical Therapy, Department of Physical Medicine and Rehabilitation, Cheng Hsin General Hospital, Taipei, Taiwan; d Graduate Institute of Pharmaceutical Science, Chia Nan University of Pharmacy & Science, Tainan, Taiwan; e Department of Physical Therapy, China Medical University, Taichung, Taiwan 1. Ching-Hsia Hung, Ph.D. Title: Associate Professor Affiliation: National Cheng Kung University Email: [email protected] Role: This author helped design the study, conduct the study, and analyze the data Conflicts: Ching-Hsia Hung reported no conflicts of interest Attestation: Ching-Hsia Hung has seen the original study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for archiving the study files 2. Chin-Chen Chu, M.D., Ph.D. Title: Assistant Professor Affiliation: Chi-Mei Medical Center Email: [email protected] Role: This author helped conduct the study and analyze the data Conflicts: Chin-Chen Chu reported no conflicts of interest Attestation: Chin-Chen Chu has seen the study data, reviewed the analysis of the data, approved the final manuscript, and is the author responsible for 2 archiving the study files 3. Yu-Chung Chen, M.S.
    [Show full text]
  • Routinely Tested Analytes
    FORENSIC TOXICOLOGY LABORATORY OFFICE OF CHIEF MEDICAL EXAMINER CITY OF NEW YORK ROUTINELY TESTED ANALYTES Listed below are drugs that are routinely included in comprehensive toxicology testing and subsequently confirmed and quantitated. (Applicable analytical methodologies are in parentheses.) VOLATILES AND GASES Ethanol (HS/GC) Acetone (HS/GC)Uncontrolled Copy 2-propanol (HS/GC) Methanol (HS/GC) Carbon monoxide (SP, CT) INCLUDED WITH POSITIVE ELISA FOR: 1. Opiates: Morphine, codeine, 6-MAM, hydrocodone, hydromorphone, oxycodone, oxymorphone (LC/MS) 2. Benzoylecgonine: cocaine, benzoylecgonine (LC/MS) 3. Barbiturates: pentobarbital, phenobarbital, secobarbital, amobarbital, butabarbital, butalbital, phenytoin, carbamazepine (HPLC) 4. Benzodiazepines: diazepam, nordiazepam, oxazepam, temazepam, alprazolam, alphahydroxyalprazolam triazolam, clonazepam, 7-aminoclonazepam, lorazepam, 7-amino flunitrazepam (GC/MS) 5. Amphetamines: amphetamine, methamphetamine, MDA, MDMA, MDEA, ephedrine, pseudoephedrine, phenylpropanlolamine, paramethoxyamphetamine. (GC/MS) 6. Oxycodone: see drugs in Opiates above plus acetaminophen (LC/MS, HPLC) 7. Methadone: methadone (and any other drugs indentified from the same extraction. 8. Cannabinoids (as needed): unconfirmed screening test BASED ON HISTORY: Vitreous chemistry: glucose, lithium Carbon monoxide Page 1 of 5 In addition to the above, the following drugs are routinely included in comprehensive toxicology testing with subsequent confirmation and quantitation. (Applicable analytical methodologies are in
    [Show full text]
  • Multiple Pharmacological Actions of Centrally Acting Antitussives — Do They Target G Protein-Coupled Inwardly Rectifying K+ (GIRK) Channels?
    J Pharmacol Sci 120, 146 – 151 (2012) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Current Perspective Multiple Pharmacological Actions of Centrally Acting Antitussives — Do They Target G Protein-Coupled Inwardly Rectifying K+ (GIRK) Channels? Kazuo Takahama1,* 1Department of Environmental and Molecular Health Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 0e-honmachi, Kumamoto 862-0973, Japan Received May 28, 2012; Accepted August 20, 2012 Abstract. Antitussive drugs have been used for decades and their modes of action are well elu- cidated. However, recent studies on the mechanism of their antitussive action seem to be opening a new way for discovery or development of novel drugs for intractable brain diseases including psychiatric disorders. Antitussives inhibit the currents caused by activation of G protein-coupled inwardly rectifying K+ (GIRK) channels in neurons. In our own studies carried out so far, we found that antitussives possessing an inhibitory action on GIRK channels, similar to the effects of an enriched environment, ameliorate symptoms of intractable brain diseases in various animal models. In this review, the multiple pharmacological actions of the antitussives are described, and their mechanisms are discussed addressing GIRK channels as a possible molecular target. Keywords: G protein-coupled inwardly rectifying K+ (GIRK) channel, centrally acting antitussive, antidepressant-like action, enriched environment, dopamine 1. Introduction tors (GPCRs) in the brain
    [Show full text]